Risk Factors for Meeting Criteria for Switching from Bevacizumab to Aflibercept When Treating Eyes with Diabetic Macular Edema and Visual Acuity of < 20/40.
- DOI
- 10.1016/j.ophtha.2024.01.037
- Published
- 2024 Aug
- Container
- Ophthalmology
- Publisher
- Not recorded
- Open access
- yes
Credibility signals
limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- cautionDOI registered: No matching Crossref record was present in this response.
- cautionDOI resolves: No matching Crossref record was present in this response.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- supportingOpen access status: Normalized open-access status: open.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty.
Cite this work
BibTeX
@article{allodium:10.1016/j.ophtha.2024.01.037,
title = {Risk Factors for Meeting Criteria for Switching from Bevacizumab to Aflibercept When Treating Eyes with Diabetic Macular Edema and Visual Acuity of < 20/40.},
author = {Jhaveri CD and Liu D and Maguire MG and Glassman AR and Grigorian RA and Jampol LM and Kingsley RM and MacCumber MW and Martin DF and Maturi RK and Velez G and Sun JK and DRCR Retina Network},
year = {2024},
journal = {Ophthalmology},
doi = {10.1016/j.ophtha.2024.01.037},
url = {https://doi.org/10.1016/j.ophtha.2024.01.037}
}RIS
TY - JOUR TI - Risk Factors for Meeting Criteria for Switching from Bevacizumab to Aflibercept When Treating Eyes with Diabetic Macular Edema and Visual Acuity of < 20/40. AU - Jhaveri CD AU - Liu D AU - Maguire MG AU - Glassman AR AU - Grigorian RA AU - Jampol LM AU - Kingsley RM AU - MacCumber MW AU - Martin DF AU - Maturi RK AU - Velez G AU - Sun JK AU - DRCR Retina Network PY - 2024 JO - Ophthalmology DO - 10.1016/j.ophtha.2024.01.037 UR - https://doi.org/10.1016/j.ophtha.2024.01.037 ER -
APA
CD, J., D, L., MG, M., AR, G., RA, G., LM, J., RM, K., MW, M., DF, M., RK, M., G, V., JK, S., & Network, D. R. (2024). Risk Factors for Meeting Criteria for Switching from Bevacizumab to Aflibercept When Treating Eyes with Diabetic Macular Edema and Visual Acuity of < 20/40.. Ophthalmology. https://doi.org/10.1016/j.ophtha.2024.01.037
Source records
- pubmed · retrieved 2026-09-26T13:52:00.301Z
- europe-pmc · retrieved 2026-09-26T13:52:00.301Z